Herborium Group Inc. (OTC:HBRM) has traded as high as $.0066 during today’s trading session and last traded at $.005 for a gain of 31.58% from yesterday’s close… HBRM shares have traded as high as $.005 over the past 52 weeks, which is 0% off that high at last traded stock price.
China Health Resource, Inc. (OTC:CHRI), issued a letter of intent to acquire up to 100% of New Jersey based Herborium Group, a Botanical Therapeutics® company quoted under the symbol HBRM. Get my next ALERT 100% FREE
“This action is a result of careful analysis of the strategy to capitalize on the need for urgent solutions in healthcare in the USA, China and globally. With healthcare costs rising and pervasive economic pressures, the need for lower cost and more effective solutions has reached critical levels. Competencies represented by Herborium will enable CHRI to bring its high quality, cost-effective and safe solutions premised on TCM to the US markets swiftly and efficiently,” says Steve Weiss, Director of Strategic Acquisitions and Financial Marketing.
Steven Weiss, as CHRI’s newly appointed Director of Strategic Acquisition and Financial Marketing says, “This potential acquisition would achieve the very first part of our goal to incorporate a strong professionally managed team to expand CHRI presence into the USA. CHRI is negotiating to purchase of a company here in my home State of New Jersey and that move will bring significant value for shareholders and a platform for bringing jobs to New Jersey which has lagged behind the rest of the nation in the creation of new jobs. This transaction will create a domestic division for China Health Care helping our economy with much needed jobs. This is the first step in building a domestic presence for CHRI upon which we will build through continued acquisitions.”
CHRI and Herborium share a common vision focused on the highest quality and value in the industry. “CHRI built its franchise through the successful standardization of Dahurian Angelica Root (DAR) for the pharmaceutical industry and has expanded into other products utilizing the same superior quality standards. CHRI is the leader in China for DAR as the only provider of GAP quality DAR in the People’s Republic of China under the registered Trademark Chuan Baizhi™. Herborium Group can greatly assist CHRI with expansion of marketing know-how as well as sales and distribution into the USA. As CHRI implements its plans to increase its product line, Herborium will add significant experience in Botanical Therapeutics® (Registered Trademark of Herborium) including the regulatory process in the USA, UK and China for our type of unique and proprietary products,” says Jiayin Wang, Chairman and CEO of CHRI.
About StockPreacher.com
StockPreacher.com is committed to producing the highest-quality insight and analysis of small cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily OTC stocks in the stock market today, which have traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.
StockPreacher Disclaimer
This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. StockPreacher.com is a wholly owned subsidiary of BlueWave Advisors. BlueWave Advisors has not been compensated, and holds no positions in any of the stocks mentioned in this article.
While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
